
    
        <!DOCTYPE html>
        <html lang="hu-HU" data-website-id="1" data-oe-company-name="HBS Medical">
            
<!-- Mirrored from hbs.hu/slides/slide/treatment-approaches-for-interstitial-cystitis-multimodality-therapy-58 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 15:59:13 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
                <meta charset="utf-8"/>
                <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"/>
                <meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no"/>

                <title>Treatment approaches for interstitial cystitis- multimodality therapy. | HBS</title>
                <link type="image/x-icon" rel="shortcut icon" href="../../web/image/website/1/favicon/index.html"/>

                <script type="text/javascript">
                    var odoo = {
                        csrf_token: "f2e9a41588799d043a772b21ddc3189150ea199fo",
                    };
                </script>

                
            <meta name="generator" content="Odoo"/>

            
            
            
            
            
            
                
                
                
                    
                        <meta property="og:type" content="website"/>
                    
                        <meta property="og:title" content="Treatment approaches for interstitial cystitis- multimodality therapy."/>
                    
                        <meta property="og:site_name" content="HBS Medical"/>
                    
                        <meta property="og:url" content="https://hbs.hu/slides/slide/treatment-approaches-for-interstitial-cystitis-multimodality-therapy-58"/>
                    
                        <meta property="og:image" content="https://hbs.hu/web/image/slide.slide/58/image_thumb"/>
                    
                        <meta property="og:description"/>
                    
                
                
                
                    
                        <meta name="twitter:card" content="summary_large_image"/>
                    
                        <meta name="twitter:title" content="Treatment approaches for interstitial cystitis- multimodality therapy."/>
                    
                        <meta name="twitter:image" content="https://hbs.hu/web/image/slide.slide/58/image_thumb"/>
                    
                        <meta name="twitter:description"/>
                    
                
            

            
            
                
                    <link rel="alternate" hreflang="hu" href="treatment-approaches-for-interstitial-cystitis-multimodality-therapy-58.html"/>
                
            

            <script type="text/javascript">
                odoo.session_info = {
                    is_admin: false,
                    is_system: false,
                    is_frontend: true,
                    translationURL: '/website/translations',
                    is_website_user: true,
                    user_id: 4
                };
                
            </script>

            <link type="text/css" rel="stylesheet" href="../../web/content/521-3ab7b2c/1/web.assets_common.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/599-e81acc7/1/web.assets_frontend.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/600-e81acc7/1/web.assets_frontend.1.css"/>
            
            
            

            <script type="text/javascript" src="../../web/content/524-3ab7b2c/1/web.assets_common.js"></script>
            <script type="text/javascript" src="../../web/content/603-e81acc7/1/web.assets_frontend.js"></script>
            
            
            
        
            </head>
            <body>
                
            
        
            
        
        
            
                
                    
                
                
            
        
        
    
    

            
            
        
    
            
          
        <link rel="stylesheet" type="text/css" href="../../sh_cookie_notice/static/src/css/cookieconsent.min.css"/>
        <script type="text/javascript" src="../../sh_cookie_notice/static/src/js/cookieconsent.min.js"></script>
        

	
	<script type="text/javascript"> 

	 window.addEventListener("load", function(){
 
	var sh_msg = String("Az HBS weboldala sütiket használ a weboldal működtetése, használatának megkönnyítése, a weboldalon végzett tevékenység nyomon követése és releváns ajánlatok megjelenítése érdekében.");
	var sh_esc_msg = encodeURIComponent(sh_msg);
	sh_esc_msg = decodeURIComponent(sh_esc_msg); 
	
  	window.cookieconsent.initialise({
	  "palette": {
	    "popup": {
	      "background": "#000" 
	    },
	    "button": {
	      "background": "#f1d600"
	    }
	  },
	  
	  	  "position": "top",
	  
	
	  
	  "content": {
	    "message": sh_esc_msg,
	    "dismiss": "Elfogadom",
	    "allow": "allow",
	    "link": "Adatvédelmi tájékoztató",
	    "href": "/adatkezelesi-tajekoztato"
	  }
	})});
    </script>
 
   
    <div id="wrapwrap" class="   ">
                <header class=" o_affix_enabled">
                    <nav class="navbar navbar-expand-md navbar-light bg-light">
                        <div class="container">
                            <a href="../../index.html" class="navbar-brand logo">
            <span role="img" aria-label="Logo of HBS Medical" title="HBS Medical"><img src="../../web/image/res.company/1/logo66cf.png?unique=866a03a" class="img img-fluid"/></span>
        </a>
    <button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#top_menu_collapse">
                                <span class="navbar-toggler-icon"></span>
                            </button>
                            <div class="collapse navbar-collapse" id="top_menu_collapse">
                                <ul class="nav navbar-nav ml-auto text-right o_menu_loading" id="top_menu">
                                    
        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../index.html" class="nav-link ">
            <span>HBS Medical</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="https://covid-19.hbs.hu" class="nav-link " target="_blank">
            <span>COVID-19</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../blog/hirek-esemenyek-1.html" class="nav-link ">
            <span>Hírek</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../aboutus.html" class="nav-link ">
            <span>Kapcsolat</span>
        </a>
    </li>
    

        
    
                                    
                                </ul>
                            </div>
                        </div>
                    </nav>
                </header>
                <main>
                    
        
        <div class="container mt16">
            <div class="row">
                <div class="col-xl-8 col-lg-8 col-md-12 col-12">
                    

                    <div>
                            
                        <div class="embed-responsive embed-responsive-4by3 embed-responsive-item mb8">
                            <iframe src="../embed/582679.html?page=1" class="o_wslides_iframe_viewer" allowFullScreen="true" height="315" width="420" frameborder="0"></iframe>
                        </div>
                        
                        <div class="row">
                            <h4 class="col-lg-6">Treatment approaches for interstitial cystitis- multimodality therapy.</h4>
                            <div class="col-lg-6">
                                <div clas="row">
                                    
                                </div>
                            </div>
                        </div>
                        <div class="row">
                            <div class="col-md-8 col-12">
                                <div class="float-left">
                                    <a href="../nyilvanos-anyagok-1.html" title="Channel Nyilvános anyagok" aria-label="Channel Nyilvános anyagok">
                                        <i class="fa fa-circle-o fa-5x" style="color: #875A7B;font-weight: bold;"></i>
                                    </a>
                                </div>
                                <div style="margin-left: 80px">
                                    <p>
                                        <a href="../nyilvanos-anyagok-1.html">Nyilvános anyagok</a>
                                        
                                            <span> / </span>
                                            <a href="../nyilvanos-anyagok-1/category/szakirodalmi-cikkek-3.html">Szakirodalmi cikkek</a>
                                        
                                    </p>
                                    <div>
                                        
        <div class="input-group js_follow" data-id="1" data-object="slide.channel" data-follow="off">
            <input type="email" name="email" class="js_follow_email form-control" placeholder="emailje..."/>
            <div class="input-group-append">
                <button href="#" class="btn btn-secondary js_unfollow_btn">Leiratkozás</button>
                <button href="#" class="btn btn-primary js_follow_btn">Feliratkozás</button>
            </div>
        </div>
    
                                    </div>
                                </div>
                            </div>
                            <div class="col-md-4 d-none d-md-block">
                                <div class="text-right">
                                    <b class="h3 text-muted">1206</b> <span class="text-muted small">views</span>
                                </div>
                                
                                <div class="progress mb0" style="height: 2px;">
                                    <div class="progress-bar" role="progressbar" aria-valuenow="0" aria-valuemin="0" aria-valuemax="100" style="width: 0%;">
                                        <span class="sr-only">0 Likes</span>
                                    </div>
                                </div>
                                <div class="text-muted mt4">
                                    <div class="float-right mb16 text-right">
                                        <span class="oe_slide_js_like" data-href="/slides/slide/like" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="58">
                                            <i class="fa fa-thumbs-up fa-1x" role="img" aria-label="Likes" title="Likes"></i>
                                            0
                                        </span>
                                        <span class="oe_slide_js_unlike" data-href="/slides/slide/dislike" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="58">
                                            <i class="fa fa-thumbs-down fa-1x" role="img" aria-label="Dislikes" title="Dislikes"></i>
                                            0
                                        </span>
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="mt8 mb32">
                            <ul class="nav nav-tabs" role="tablist">
                                <li class="nav-item">
                                    <a href="#about" aria-controls="about" role="tab" data-toggle="tab" class="nav-link active">
                                        <i class="fa fa-home"></i> About
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#share" aria-controls="share" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-share-alt"></i> Share
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#discuss" aria-controls="discuss" role="tab" data-toggle="tab" class="nav-link">
                                        <i class="fa fa-comments-o"></i> Comments
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#transcript" aria-controls="transcript" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-align-justify"></i> Transcript
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#statistic" aria-controls="statistic" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-bar-chart"></i> Statistics
                                    </a>
                                </li>
                            </ul>
                            <div class="tab-content" style="padding: 20px 5px 5px 5px; word-wrap: break-word;">
                                <div role="tabpanel" id="about" class="tab-pane fade active in">
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="share">
                                    
    <h4 class="mt0">Share on Social Networks</h4>
    
    <div>
        <a class="o_slides_social_share" social-key="facebook" aria-label="Share on Facebook" title="Share on Facebook" href="https://www.facebook.com/sharer/sharer.php?u=https://hbs.hu/r/RSm"><i class="fa fa-facebook-square fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="twitter" aria-label="Share on Twitter" title="Share on Twitter" href="https://twitter.com/intent/tweet?text=Treatment%20approaches%20for%20interstitial%20cystitis-%20multimodality%20therapy.&amp;url=https://hbs.hu/r/RSm"><i class="fa fa-twitter fa-2x"></i></a>
        <a social-key="linkedin" class="o_slides_social_share" aria-label="Share on LinkedIn" title="Share on LinkedIn" href="https://www.linkedin.com/shareArticle?mini=true&amp;url=https://hbs.hu/r/RSm&amp;title=Treatment%20approaches%20for%20interstitial%20cystitis-%20multimodality%20therapy.&amp;"><i class="fa fa-linkedin fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="gplus" aria-label="Share on Google Plus" title="Share on Google Plus" href="https://plus.google.com/share?url=https://hbs.hu/r/RSm"><i class="fa fa-google-plus-square fa-2x"></i></a>
    </div>

    <h4 class="mt-3">Share Link</h4>
    <input type="text" class="form-control" readonly="readonly" onClick="this.select();" value="treatment-approaches-for-interstitial-cystitis-multimodality-therapy-58.html"/>
    <span class="form-text">Use permanent link to share in social media</span>

                                    
    <h4 class="mt-3">Share with a friend</h4>
    
    
        <p>Please <a href="../../web/login.html?redirect=https://hbs.hu/slides/slide/treatment-approaches-for-interstitial-cystitis-multimodality-therapy-58"> login </a> to send this document by email!</p>
    

                                    
                                        
    <div class="oe_slide_js_embed_code_widget">
        <h4 class="mt0">Embed in your website</h4>
        <div class="form-group">
            <textarea class="form-control slide_embed_code" readonly="readonly" onClick="this.select();">&lt;iframe src=&quot;https://hbs.hu/slides/embed/58?page=1&quot; class=&quot;o_wslides_iframe_viewer&quot; allowFullScreen=&quot;true&quot; height=&quot;315&quot; width=&quot;420&quot; frameborder=&quot;0&quot;&gt;&lt;/iframe&gt;</textarea>
        </div>
        <div class="form-group">
            <div class="form-text col-xl-3 col-lg-3 col-md-6 col-6">Select page to start with</div>
            <div class="input-group col-xl-3 col-lg-3 col-md-6 col-6">
                <input type="number" value="1" class="form-control"/>
            </div>
        </div>
    </div>

                                    
                                </div>
                                
                                <div role="tabpanel" id="discuss" class="tab-pane fade">
                                    
        <div id="discussion" class="d-print-none o_portal_chatter o_not_editable p-0" data-res_model="slide.slide" data-res_id="58" data-pager_step="10" data-allow_composer="1">
        </div>
    
                                </div>
                                <div role="tabpanel" class="tab-pane fade oe_slides_transcript" id="transcript">
                                    
                                        
                                            <p>2. VOL. 4 SUPPL. 1  2002    REVIEWS IN UROLOGY    S17 Multimodality Therapy for IC A large number of therapies are available to treat patients with IC. Because of variation in response to therapy, the clinical approach to treatment has been largely empirical. Increased understanding of the etiol- ogy of IC and identification of factors involved in the pathophysiology of the disease will allow treatment reg- imens to be better targeted toward each individual patient’s conditions.  A Proposed Model for IC Pathogenesis Many theories have been proposed to explain the pathogenesis of IC, but none have been conclusively proven to be true. Proposed causative factors include epithelial dysfunction, 3 mast cell abnormalities, 5 subclinical infec- tion, 4 neurogenic inflammation, 6 vas- cular abnormalities, 7 and autoimmune phenomena. 2 With so many possible factors influencing the development of IC, it is likely that there is not a single etiology for the disease. It is far more likely that the etiology is multifactorial. A model has been pro- posed for the development of IC that takes into account not only the experimental data currently available concerning the possible mechanisms for the development of IC, but also the clinical histories commonly seen in this patient population (see Figure 1). 8 In this proposed model, the cascade of events that lead to the develop- ment of clinical IC begins with the development of an injury to the bladder or epithelium. In many cases this may have occurred following an episode of bacterial cystitis, but in other patients, pelvic surgery, child- birth, or urologic instrumentation may be the initiating event. In normal patients, uroepithelium is expected to heal following appropriate therapy, but in this group of patients healing of the uroepithelium does not occur. Recent reports have suggested that patients with IC have urine that con- tains an anti-proliferative factor that retards or prevents normal epithelial healing. 9 In addition, epithelial growth factor is decreased in urine of IC patients. This combination of elevated anti-proliferative factor and dimin- ished epithelial growth factor seems to prevent normal uroepithelial repair. Over time, these patients develop abnormalities of the glycosamino- glycan (GAG) layer. Parsons has demonstrated that IC patients suffer from a defective GAG layer that allows urinary metabolites such as potassium to pass through the bladder wall and into the submucosal space. 10 Potassium leaking through the uroepithelium causes depolarization of smooth muscles of the bladder and the pelvis, with activation of sensory nerves. The constant irritation of the submucosal space by leakage of urinary metabolites through the defective bladder lining causes an inflammatory reaction marked by the proliferation and activation of sub- mucosal mast cells. When activated, mast cells release histamine and other mediators, stimulating sensory nerve fibers and eliciting local tissue damage and vascular constriction.  Mast cell degranulation activates capsacin-sensitive nerve fibers, lead- ing to the release of substance P as well as other neuropeptides, causing additional cell damage and further activation of mast cells. Over time, the ongoing effects of both the mast cell activation and the stimulation of the capsacin fibers are more local tis- sue damage, ongoing injury to the GAG layer, further injury to the blad- der smooth muscle, and development of fibrotic changes within the bladder. Over time, if this cascade of events is left untreated, the bladder will decrease in size and the functional bladder capacity will plummet. The inflammation and activation of the capsacin fibers can lead to neural up-regulation and the devel- opment of neural changes within the spinal cord. Once this occurs, patients will suffer from chronic pelvic pain, urgency, and frequency. The “up-reg- ulation&quot; that occurs in patients with long-standing IC explains why many patients continue to have vaginal and pelvic pain even after cystectomy. Although it is not clear why this cascade of events occurs in this Figure 1 . A proposed model for the pathogenesis of interstitial cystitis.  Bladder insult Epithelial layer damage interstitium Potassium leak into Activation of C-fibers and  release of substance P Mast cell activation and   histamine release More injury </p>
                                        
                                            <p>1. S16    VOL. 4 SUPPL. 1  2002    REVIEWS IN UROLOGY  I nterstitial cystitis (IC) is a bladder condition that presents with a range of symptoms, including bladder pain, urinary urgency and frequency, and noc- turia. Current estimates of disease prevalence suggest that at least 1 million people in the United States are affected. 1 The etiology remains uncertain, although a number of potential causal factors have been proposed. 2–7 The variation seen in both the range of symptoms and in patients’ responses to therapy suggest that multiple factors are involved in this disease process. There remains the possibility that subgroups of patients may exist with differing etiologies. Treatment Approaches for Interstitial Cystitis: Multimodality Therapy Robert J. Evans, MD  Moses Cone Health System, Greensboro, NC Interstitial cystitis is an increasingly common disease characterized by urgency, frequency, and pelvic pain. Its etiology is poorly understood but is likely to be multifactorial. A proposed pathophysiology describing a cascade of events, including epithelial dysfunction, mast cell activation, and neurogenic inflam- mation, is presented. Using this model, multimodality therapy regimens have been developed that treat all components of this cascade. Multimodality therapy appears more effective than single agents in the treatment of interstitial cystitis. [Rev Urol . 2002;4(suppl 1):S16–S20 ] © 2002 MedReviews, LLC Key words : Interstitial cystitis  • Multimodality therapy  • Pentosan polysulfate  • Hydroxyzine hydrochloride  • Amitriptyline hydrochloride C LINICAL M ANAGEMENT OF I NTERSTITIAL C YSTITIS </p>
                                        
                                            <p>4. VOL. 4 SUPPL. 1  2002    REVIEWS IN UROLOGY    S19 Multimodality Therapy for IC thomimetic effect of this agent often exacerbates dysfunctional voiding.  Patients who truly cannot tolerate tricyclic antidepressants may benefit from the administration of selective serotonin reuptake inhibitor (SSRI) antidepressants. This is particularly true for patients who also suffer from fibromyalgia. Commonly used SSRIs include paroxetine hydrochloride, fluoxetine hydrochloride, citalopram hydrobromide, venlafaxine hydrochlo- ride, and sertraline hydrochloride. There have been no placebo-controlled trials for SSRI as treatment for IC. Gabapentin Pain and dysfunctional voiding may continue even after appropriate ther- apy with pentosan polysulfate and other agents. This may be due to “up-regulation&quot; and the development of neurogenic inflammation within the spinal cord. Gabapentin can decrease neurogenic inflammation and is used in patients with severe and unrelenting chronic pain. 17 It is usually given in divided doses rang- ing from 300 mg to 2400 mg daily. This drug requires very careful dose titration, balancing symptom control with side effects such as sedation. If a urologist is uncomfortable using agents of this nature, referral to a pain clinic is appropriate. Phenytoin, carbamazepine, and valproic acid are alternatives to gabapentin. Supplementary Oral  Therapies Urinary analgesics and antiseptics such as phenazopyridine hydrochlo- ride, Uromax, and Urised are not effective as primary therapy, but can be helpful for the management of short-term symptom flares or after urologic instrumentation. Other agents that are occasionally helpful include urinary alkalizers, which can decrease bladder discomfort by lowering uri- nary acidity. Pelvic floor dysfunction is often present concomitantly with IC. Benzodiazopines or other skeletal muscle relaxants are appropriate therapy. Moldwin has demonstrated that doses as low as 2 mg t.i.d. of diazapam can relax the pelvic floor and ease dysfunctional voiding (per- sonal communication, RM Moldwin). Anecdotal use of alpha blockers, including tamsulosin hydrochloride, for male and female patients with dysfunctional voiding may be bene- ficial, but no controlled studies have been completed. Intravesical Agents For patients who do not respond to oral therapy or for those patients who suffer from a flare and require addi- tional treatment, several intravesi- cal  agents are available. Although dimethyl sulfoxide (DMSO) is the prin- ciple intravesical agent approved by the U.S. Food and Drug Administration (FDA), numerous other agents have been used. 18 DMSO is generally administered once weekly for at least 6 weeks, and administration can be done either in the clinic or at home by patients capable of self-catheteri- zation. Multidrug cocktails, including DMSO (50 cc), sodium bicarbonate (48 meq), heparin (20,000 units), and triamcinolone acetonide (1 amp) are Figure 2 . The role of multimodality therapy as related to the proposed multifactorial etiology of interstitial cystitis. Epithelial layer damage Bladder insult Pentosan Pentosan polysulfate  polysulfate  sodium sodium More injury Mast cell activation and histamine release Antihistamine Antihistamine therapy therapy Tricyclic Tricyclic therapy therapy Activation of C-fibers and  release of substance P Potassium leak into interstitium Figure 3 . A summary of multimodality therapy for interstitial cystitis. •  Diet and Self Help Pathogenic Factor                     Therapy Epithelial dysfunction            Pentosan polysulfate Neuromodulation                     Antidepressants Mast cell activation                  Antihistamines •  Don’t withdraw therapy when adding new modalities </p>
                                        
                                            <p>3. S18    VOL. 4 SUPPL. 1  2002    REVIEWS IN UROLOGY  Multimodality Therapy for IC continued patient population, this theory of a multifactorial etiology for IC is extremely helpful in planning effective therapy. To prevent the development of end-stage IC, aggressive and early detection, combined with a multi- modality therapy approach to address not only the deficiency of the GAG layer but also mast cell abnormalities and neurogenic inflammation, may help stop the progression of the dis- ease and over time allow for the redevelopment of a more normally functioning bladder epithelium. Implementing a Multimodality Treatment Strategy Given the multifactorial nature of IC, it is unusual for patients, particularly those with more severe disease, to respond to a single agent. It is crucial to utilize a multimodality treatment strategy in selecting appropriate therapy for IC. In patients who are candidates for long-term oral therapy, select agents that will treat GAG layer dysfunction, mast cell abnor- malities, and neurogenic inflamma- tion (see Table 1). The side effects of the medications selected need to be considered so that if two medications have similar side effects, such as sedation, dose modifications may be made. Table 2 lists the components of oral therapy discussed below. Pentosan Polysulfate Pentosan polysulfate (PPS) remains the cornerstone of drug therapy for most patients. Although the exact nature of PPS on the bladder is not completely clear, it is felt to function by coating the bladder lining, re-estab- lishing normal GAG layer function and decreasing potassium leak into the interstitial space. 11 The recom- mended dose is 100 mg t.i.d., but higher doses such as 200 mg t.i.d. or 300 mg t.i.d. have been used. Alternative dosing schedules to improve patient compliance have been used at many IC centers, with 200 mg b.i.d. a common starting dose.  Patients starting therapy with PPS need to be told that the full effect may not be seen for 6–9 months, but they can be reassured that many patients see improvement in as little as 4 weeks. Patients taking PPS need to be encouraged to stick with therapy, because the most important factor in determining the benefit of therapy with PPS is the length of time under treatment. Patients on PPS need to be reassured that the side effects sometimes seen with this medication (including headache, gastrointestinal upset, and hair loss) are generally mild and usually will not necessitate withdrawal of the medication.  Antihistamines The central role of the mast cell in IC is clear. 12 Any form of multimodality therapy should include therapy that blocks the effect of histamine. Hydroxyzine hydrochloride remains the most effective agent for the man- agement of mast cell dysfunction. 13 Because of its sedative properties, it is generally administered at night in doses ranging from 25 to 75 mg. In patients who are highly sensitive, doses as low as 10 mg can be used. In the spring and fall, when many IC patients suffer from seasonal aller- gies, an additional 10–25 mg every 6 hours can be beneficial. In patients who cannot tolerate a sedating anti- histamine, cetirizine hydrochloride may be a reasonable alternative. The addition of H2 blockers to more standard antihistamine therapy has been reported, but the results are somewhat inconclusive. 14 Antidepressants IC patients often benefit from an antidepressant therapy, particularly tricyclic antidepressants such as amitriptyline hydrochloride. 15 These antidepressants are particularly effective, because in addition to the antidepressant effect they modify pain, have a mild antihistamine effect, can decrease urgency and frequency through a modest anticholinergic effect, and are also effective as  sleep aids. 16 Amitriptyline is generally administered at night in doses ranging from 25 to 100 mg q.h.s. with dose titration over time until adequate symptom control is achieved. If patients are also taking an antihista- mine the dose may need to be decreased, with some patients respond- ing to doses as low as 10 mg  q.h.s. If patients cannot tolerate amitriptyline they may respond to alternative tricyclics, including tra- zodone, doxepin, and nortriptyline. One antidepressant that should be avoided is imipramine, as the sympa- Table 1 Principles of Multimodality Therapy for Intersitial Cystitis  Repair endothelial dysfunction  Modulate neural activity  Stabilize mast cells Table 2 Components of Oral Therapy  for Interstitial Cystitis  Pentosan polysulfate  Antihistamines  Antidepressants  Anticholinergics  Urinary analgesics  Narcotics/pain relievers  Gabapentin  Other </p>
                                        
                                            <p>5. S20    VOL. 4 SUPPL. 1  2002    REVIEWS IN UROLOGY  Multimodality Therapy for IC continued commonly used. For patients who are capable of self-catheterization, an anesthetic cocktail consisting of bupivacaine (30 cc), heparin (20,000 units), sodium bicarbonate (48 meq), and triamcinolone acetonide (1 amp) can be self-administered on a daily basis. Patients who are unable to take pentosan polysulfate because of side effects may respond to either intravesical pentosan polysulfate or intravesical heparin administered daily. 19 Intravesical oxybutynin (5–10 mg crushed and suspended in 10 cc of water) has also been used to control bladder spasms. Other intravesical agents not FDA approved include hyaluronidase 20 and bacillus Calmette-Guérin (BCG). 21 A clinical trial of hyaluronidase is cur- rently underway, and it is anticipated that a BCG trial will commence shortly. Discussion A majority of patients will respond to a multidisciplinary approach con- sisting of dietary modification, behavioral modification, pentosan polysulfate, and either hydroxyzine, a tricyclic antidepressant, or both (Figures 2 and 3). If patients respond to multimodality therapy, they can be slowly weaned from their medications. Narcotics, neuroleptics, and antide- pressants are eliminated first. If patients tolerate this, continue to sleep well, and have good pain control, their antihistamine dose can be decreased and possibly eliminated. The pentosan polysulfate dose can also be titrated downward. Although some patients can eliminate all med- ications and do well, most require a maintenance dose of pentosan poly- sulfate, often as little as one or two pills daily. Patients are encouraged to follow their IC diet carefully and con- tinue with stress management tech- niques. If at any time symptoms flare, their medications can be temporarily increased and then once again decreased back to baseline once the symptom flare has been controlled. Conclusion The proposed multifactorial etiology of IC has led to the development of an appropriate multimodality therapy for the disease. Most patients will respond to this multimodal approach with significant improvement and in general can tolerate this treatment regimen in the long term.  References 1.     Jones CA, Nyberg L. Epidemiology of intersti- tial cystitis.  Urology . 1997;49(suppl 5A):2–9. 2.     Oravisto KJ. Interstitial cystitis as an autoim- mune disease: a review.  Eur Urol.  1980;6:10–13. 3.    Parsons CL, Lilly JD, Stein P. Epithelial dys- function in nonbacterial cystitis (interstitial cystitis).  J Urol. 1991;145:732–735.  4.     Warren JW. Interstitial cystitis as an infectious disease. Urol Clin North Am. 1994;21:31–39. 5.     Sant GR, Theoharides TC. The role of the mast cell in interstitial cystitis. Urol Clin North Am . 1994;21:41–53. 6.     Pang X, Marchand J, Sant GR, Theoharides TC. Increased number of substance P positive fibers in interstitial cystitis.  Br J Urol . 1995;75:744–750. 7.    Hohenfeller M, Nunes L, Schmidt RA, et al. Interstitial cystitis: increased sympathetic innervation and related neuropeptide synthesis. J Urol. 1992;147:587–589. 8.     Keay S, Warren JW. A hypothesis for the etiol- ogy of interstitial cystitis based upon inhibition of bladder epithelial repair.  Med Hypotheses. 1998;51:79–83. 9.     Keay SK, Zhang C, Shoenfelt J, et al. Sensitivity and specificity of antiproliferative factor, heparin-binding epidermal growth factor-like growth factor and epidermal growth factor as unique markers for interstitial cystitis.  Urology . 57(6 suppl 1):9–14. 10.    Lilly JD, Parsons CL. Bladder surface gly- cosaminoglycans: a human epithelial perme- ability barrier.  Surg Gynecol Obstet. 1990;174:493–496. 11.    Parsons CL, Benson G, Childs SJ, et al. A quan- titatively controlled method to prospectively study interstitial cystitis and demonstrate the efficacy of pentosan polysulfate.  J Urol. 1993;150:845–848. 12.   Theoharides TC, Sant GR, El-Monsoury M, et al. Activation of bladder mast cells in interstitial cystitis: a light and electron microscopic study. J Urol . 1995;153:629–636. 13.   Theoharides TC, Sant GR. Hydroyzine therapy for interstitial cystitis.  Urol.  1997;49(suppl 5A):108–109. 14.   Seshadri P, Emerson L, Morales A. Cimetidine in the treatment of interstitial cystitis.  Urol. 1994;44:614–616. 15.   Hanno PM. Amitriptyline in the treatment of interstitial cystitis.  Urol Clin North Am . 1994;21:89–92. 16. W atson CPN. Antidepressants as ajunctive analgesics.  J Pain Symptom Manage. 1994;9:392–415. 17.   Brookoff D. The causes and treatment and pain in interstitial cystitis. In: Sant GR, ed. Interstitial Cystitis. Philadelphia: Lippincott- Raven; 1997:177–192. 18.    Parkin J, Shea C, Sant GR. Intravesical dimethyl sulfoxide (DMSO) for interstitial cystitis—a practical approach.  Urology . 1997;49(suppl 5A):105–107. 19.   Parsons CL, Housley T, Schmidt JD, Lebow D. Treatment of interstitial cystitis with intravesi- cal heparin.  Br J Urol. 1994;73:504–507. 20.   Peters KM, Diokno AC, Steinert BW, Gonzalez JA. The efficacy of intravesical bacillus Calmette-Guérin in the treatment of interstitial cystitis: long-term follow up.  J Urol. 1998;159:1483–1486. 21.   Morales A, Emerson L, Nickels JC. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis.  Urol . 1997;49(suppl 5A):111–113. Main Points • A multifactorial model has been proposed for the development of interstitial cystitis (IC). • In this model, an injury to the bladder or epithelium of the IC patients does not heal normally; leakage of urinary metabolit es through the defective bladder lining causes mast cell activation and neurogenic inflammation; over time, if this cascade of eve nts is left untreated, the bladder will decrease in size and the functional bladder capacity will plummet. • When treating patients with IC, it is crucial to utilize a multimodality treatment strategy, including agents that will treat  gly- cosaminoglycan (GAG) layer dysfunction, mast cell abnormalities, and neurogenic inflammation. • Pentosan polysulfate remains the cornerstone of drug therapy for most patients; it functions by coating the bladder lining, r e- establishing normal GAG layer function and decreasing potassium leak into the interstitial space. Urinary analgesics and antise ptics, urinary alkalizers, and benzodiazopines can also be useful in some settings. • For patients who do not respond to oral therapy or for those patients who suffer from a flare and require additional treatmen t, several intravesical agents are available. </p>
                                        
                                            <p></p>
                                        
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="statistic" slide-url="treatment-approaches-for-interstitial-cystitis-multimodality-therapy-58.html">
                                    <div class="row">
                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Nézetek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">1206</span>
                                                    <i class="fa fa-play"></i> Total Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">886</span>
                                                    <i class="fa fa-circle-o"></i> Website Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">320</span>
                                                    <i class="fa fa-code"></i> Embedded Views
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Műveletek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="total-share">0</span>
                                                    <i class="fa fa-share-alt"></i> Social Shares
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-up"></i> Likes
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-down"></i> Nemkedvelések
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-comments-o"></i> Comments
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Share count</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="facebook-badge">0</span>
                                                    <i class="fa fa-facebook-square"></i> Facebook
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="twitter-badge">0</span>
                                                    <i class="fa fa-twitter-square"></i> Twitter
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="linkedin-badge">0</span>
                                                    <i class="fa fa-linkedin-square"></i> LinkedIn
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="google-badge">0</span>
                                                    <i class="fa fa-google-plus-square"></i> Google+
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                    <div class="row">
                                        <div class="col-lg-12">
                                            <h4 class="mt0"> Embeds
                                                <span class="badge badge-pill float-right">
                                                    4
                                                </span>
                                            </h4>
                                            <ul class="list-group" style="height: 150px;overflow: auto;">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">14</span>
                                                    hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">4</span>
                                                    www.hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">1</span>
                                                    novotrade.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">2</span>
                                                    odoo.hbs.hu
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                <div class="col-xl-4 col-lg-4 col-md-12 col-12">
                    <ul class="nav nav-tabs" role="tablist">
                        <li class="nav-item"><a aria-controls="related" href="#related" class="nav-link active" data-toggle="tab">Kapcsolódó</a></li>
                        <li class="nav-item"><a aria-controls="most_viewed" href="#most_viewed" class="nav-link" data-toggle="tab">Most Viewed</a></li>
                    </ul>
                    <div class="tab-content">
                        <div role="tabpanel" id="related" class="tab-pane active mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1557 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1503 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/19/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html"><h6 class="mb-1">Cikk a Neurourology and Urodynamics-ban 2018.</h6></a>
            <small class="text-muted">
                1472 Views . <timeago class="timeago" datetime="2019-10-31 13:28:23.618732"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1497 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-diagnostic-algorhytm-21.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/21/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-diagnostic-algorhytm-21.html"><h6 class="mb-1">IC-BPS diagnostic algorhytm.</h6></a>
            <small class="text-muted">
                1486 Views . <timeago class="timeago" datetime="2019-10-31 13:29:57.450898"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="glycosaminoglycan-therapy-for-bladder-diseases-22.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/22/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="glycosaminoglycan-therapy-for-bladder-diseases-22.html"><h6 class="mb-1">Glycosaminoglycan Therapy for Bladder Diseases</h6></a>
            <small class="text-muted">
                1383 Views . <timeago class="timeago" datetime="2019-10-31 13:30:10.980936"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="essic-2017-budapest-abstracts-23.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/23/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="essic-2017-budapest-abstracts-23.html"><h6 class="mb-1">ESSIC 2017 Budapest abstracts</h6></a>
            <small class="text-muted">
                1462 Views . <timeago class="timeago" datetime="2019-10-31 13:30:38.129948"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/24/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html"><h6 class="mb-1">Prevalence of Symptoms of Bladder Pain Syndrome 2011</h6></a>
            <small class="text-muted">
                1302 Views . <timeago class="timeago" datetime="2019-10-31 13:30:57.131521"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/25/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html"><h6 class="mb-1">The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment. 2017</h6></a>
            <small class="text-muted">
                1360 Views . <timeago class="timeago" datetime="2019-10-31 13:35:55.689470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/26/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html"><h6 class="mb-1">Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass-Spectrometry Based Metabolomics Analysis. 2016</h6></a>
            <small class="text-muted">
                1297 Views . <timeago class="timeago" datetime="2019-10-31 13:36:14.959707"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/27/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html"><h6 class="mb-1">PENTOSAN POLYSULFATE SODIUM FOR THERAPY of IC Urology 1990</h6></a>
            <small class="text-muted">
                1412 Views . <timeago class="timeago" datetime="2019-10-31 13:37:27.415502"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/28/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html"><h6 class="mb-1">Interstitial cystitis intravesical therapy tau-06-S2-S171 2017</h6></a>
            <small class="text-muted">
                1366 Views . <timeago class="timeago" datetime="2019-10-31 13:38:04.204366"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/29/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html"><h6 class="mb-1">Novel targeted bladder drug-delivery systems rru-7-169 2015</h6></a>
            <small class="text-muted">
                1487 Views . <timeago class="timeago" datetime="2019-10-31 13:38:18.425299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/30/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html"><h6 class="mb-1">Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections 2016 bmjopen-2015-009669</h6></a>
            <small class="text-muted">
                1219 Views . <timeago class="timeago" datetime="2019-10-31 13:38:52.835202"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/31/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html"><h6 class="mb-1">Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections- Results from a multicentre survey.cuaj-9-10-e721</h6></a>
            <small class="text-muted">
                1386 Views . <timeago class="timeago" datetime="2019-10-31 13:39:08.628954"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/32/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html"><h6 class="mb-1">IC_BPS and glycosaminoglycans replacement therapy 2015 tau-04-06-638</h6></a>
            <small class="text-muted">
                1249 Views . <timeago class="timeago" datetime="2019-10-31 13:39:22.993300"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/33/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html"><h6 class="mb-1">Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans- an update on the evidence 2016 Urology</h6></a>
            <small class="text-muted">
                1387 Views . <timeago class="timeago" datetime="2019-10-31 13:40:52.836690"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/34/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html"><h6 class="mb-1">Hyaluronic Acid and Its Composites as a Local Antimicrobial-Antiadhesive Barrier 2017.jbjiv02p0063</h6></a>
            <small class="text-muted">
                1309 Views . <timeago class="timeago" datetime="2019-10-31 13:45:41.648470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/35/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html"><h6 class="mb-1">Evidence-based criteria for the pain of IC_BPS in women 2008 nihms43157</h6></a>
            <small class="text-muted">
                1299 Views . <timeago class="timeago" datetime="2019-10-31 13:45:59.326213"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/36/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html"><h6 class="mb-1">Intravesical Glycosaminoglycan Replacement with Chondroitin_2015_Article_306</h6></a>
            <small class="text-muted">
                1357 Views . <timeago class="timeago" datetime="2019-10-31 13:46:19.773972"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                        <div role="tabpanel" id="most_viewed" class="tab-pane  mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="sugarvedo-ruhazat-ismerteto-3.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/3/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="sugarvedo-ruhazat-ismerteto-3.html"><h6 class="mb-1">Sugárvédő ruházat ismertető</h6></a>
            <small class="text-muted">
                3283 Views . <timeago class="timeago" datetime="2018-10-20 14:31:25.547995"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="op-set-system-5.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/5/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="op-set-system-5.html"><h6 class="mb-1">OP Set System</h6></a>
            <small class="text-muted">
                3042 Views . <timeago class="timeago" datetime="2018-11-16 13:38:03.543744"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kompresszios-polya-felhelyezese-8.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/8/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kompresszios-polya-felhelyezese-8.html"><h6 class="mb-1">Kompressziós pólya felhelyezése</h6></a>
            <small class="text-muted">
                2845 Views . <timeago class="timeago" datetime="2018-11-16 13:39:25.884480"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kotszer-polya-l-r-6.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/6/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kotszer-polya-l-r-6.html"><h6 class="mb-1">Kötszer Pólya L&amp;R</h6></a>
            <small class="text-muted">
                2642 Views . <timeago class="timeago" datetime="2018-11-16 13:38:35.611223"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="nedves-sebkezeles-flyer-l-r-7.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/7/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="nedves-sebkezeles-flyer-l-r-7.html"><h6 class="mb-1">Nedves sebkezelés flyer L&amp;R</h6></a>
            <small class="text-muted">
                2437 Views . <timeago class="timeago" datetime="2018-11-16 13:38:59.835920"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-liner-10.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/10/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-liner-10.html"><h6 class="mb-1">PDB_Actico UlcerSys Liner</h6></a>
            <small class="text-muted">
                2323 Views . <timeago class="timeago" datetime="2018-11-16 13:39:54.728282"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-2.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/2/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-2.html"><h6 class="mb-1">SciCan STATIM G4</h6></a>
            <small class="text-muted">
                2320 Views . <timeago class="timeago" datetime="2018-10-20 14:10:02.671163"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-9.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/9/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-9.html"><h6 class="mb-1">PDB_Actico UlcerSys</h6></a>
            <small class="text-muted">
                2208 Views . <timeago class="timeago" datetime="2018-11-16 13:39:42.488113"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-hasznalati-utmutato-v1-1-12.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/12/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-hasznalati-utmutato-v1-1-12.html"><h6 class="mb-1">UroStill_hasznalati_utmutato_v1.1</h6></a>
            <small class="text-muted">
                2037 Views . <timeago class="timeago" datetime="2019-10-31 13:22:24.531510"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="koronavirus-jarvany-61.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/61/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="koronavirus-jarvany-61.html"><h6 class="mb-1">KORONAVIRUS JARVANY</h6></a>
            <small class="text-muted">
                1773 Views . <timeago class="timeago" datetime="2020-04-09 15:16:22.317496"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-1.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/1/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-1.html"><h6 class="mb-1">SciCan Statim G4</h6></a>
            <small class="text-muted">
                1708 Views . <timeago class="timeago" datetime="2018-10-20 14:09:31.661802"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="new-aiding-device-for-self-instillation-v2-16.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/16/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="new-aiding-device-for-self-instillation-v2-16.html"><h6 class="mb-1">New_aiding_device_for_self-instillation_v2</h6></a>
            <small class="text-muted">
                1689 Views . <timeago class="timeago" datetime="2019-10-31 13:23:48.863175"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kitpack-11.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/11/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="kitpack-11.html"><h6 class="mb-1">Kitpack</h6></a>
            <small class="text-muted">
                1684 Views . <timeago class="timeago" datetime="2018-11-16 14:52:39.736537"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="icbps-szoszedet-14.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/14/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="icbps-szoszedet-14.html"><h6 class="mb-1">ICBPS_SZÓSZEDET</h6></a>
            <small class="text-muted">
                1617 Views . <timeago class="timeago" datetime="2019-10-31 13:23:06.826135"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/15/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html"><h6 class="mb-1">IC - FAQ-s and appropriate answers Mumbai 2019</h6></a>
            <small class="text-muted">
                1611 Views . <timeago class="timeago" datetime="2019-10-31 13:23:19.219912"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-users-manual-v1-1-13.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/13/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-users-manual-v1-1-13.html"><h6 class="mb-1">UroStill_Users_Manual_v1.1</h6></a>
            <small class="text-muted">
                1604 Views . <timeago class="timeago" datetime="2019-10-31 13:22:47.677753"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="l-r-corporate-film-4.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/4/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="l-r-corporate-film-4.html"><h6 class="mb-1">L&amp;R Corporate Film</h6></a>
            <small class="text-muted">
                1601 Views . <timeago class="timeago" datetime="2018-11-14 15:53:51.760680"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1557 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1503 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1497 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    
                </main>
                <footer class="bg-light o_footer">
                    <div id="footer" class="oe_structure oe_structure_solo">
      <section class="s_text_block pb8 pt40">
        <div class="container">
          <div class="row" style="border-top: solid 1px #ddd; padding-top: 30px;">
            <div class="col-lg-4">
              <h5>További tartalmak</h5>
              <ul class="list-unstyled">
                <li>
                  <a href="../../blog/hirek-esemenyek-1.html" data-original-title="" title="" aria-describedby="tooltip310735">Hírek</a>
                  <br/>
                  <a href="../../adatkezelesi-tajekoztato.html">Adatkezelési tájékoztató</a>
                </li>
                <li>
                  <br/>
                </li>
              </ul>
            </div>
            <div class="col-lg-4" id="connect">
              <h5>Elérhetőségek</h5>
              <ul class="list-unstyled">
                <li>
                  <i class="fa fa-phone"></i>
                  <span data-note-id="2">+36 1 452 1700</span>
                </li>
                <li>
                  <i class="fa fa-envelope"></i>
                  <span><a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="11787f777e517973623f7964">[email&#160;protected]</a></span>
                </li>
              </ul>
              <p> </p>
            </div>
            <div class="col-lg-4">
              <h5>
                <span>HBS Medical</span>
                <small> – <a href="../../aboutus.html" data-original-title="" title="" aria-describedby="tooltip425138">Kapcsolat</a></small>
              </h5>
              <p>&nbsp;<br/></p>
            </div>
          </div>
        </div>
      </section>
    </div>
  <div class="o_footer_copyright">
            <div class="container">
                <div class="row">
                    <div class="col-lg-6 text-muted text-center text-md-left">
                        <span>Copyright &copy;</span> <span itemprop="name">HBS Medical</span>
                        
    

                    </div>
                    <div class="col-lg-6 text-right o_not_editable">
                        
    <!--<div class="o_brand_promotion text-muted">
        Az oldalt készítette:
        <a href="https://eyssen.hu/" target="_blank"><img src="../../web/image/606/eyssen_logo_blue.png" width="120"/></a>
    </div>-->

                    </div>
                </div>
            </div>
        </div>
    </footer>
            </div>
        <script data-cfasync="false" src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script id="tracking_code">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

            ga('create', _.str.trim('UA-52898474-1'), 'auto');
            ga('send','pageview');
        </script>
    
        
            </body>
        
<!-- Mirrored from hbs.hu/slides/slide/treatment-approaches-for-interstitial-cystitis-multimodality-therapy-58 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 15:59:18 GMT -->
</html>
    
    
